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ABSTRACT 
 
Background: Type 2 Diabetes Mellitus (T2DM) represents one of the most important risk factors 
for atrial fibrillation (AF). Numerous studies have shown that T2DM and poor glycemic control 
reflected by glycated hemoglobin A1c (HbA1c) levels are independently associated with new onset 
AF. Recent experimental studies reported that the increased susceptibility to AF in the diabetic 
patients was presumably due to the slowing of conduction associated with increased interstitial 
ﬁbrosis. Systemic inflammation cam play role in the development of atrial fibrillation. High-
sensitivity C-reactive protein (hsCRP) is an inflammatory biomarker that independently predicts 
the cardiovascular risk. This study aimed to determine the association between hsCRP level and 
glycemic control with total interatrial conduction time in T2DM patients. 
Subjects and Method: This was an observational analytic study with cross-sectional design. A 
total of samples were 41 patients with T2DM. Peripheral venous blood samples to measure hsCRP 
and HbA1c were drawn in all study population. The total interatrial conduction time was measured 
by tissue Doppler echocardiography. Multivariate analysis was performed using multiple regression 
analysis. p< 0.050 was considered to indicate a statistically significant difference.  
Results: The high-sensitivity C-reactive protein level was higher in the T2DM patients with 
HbA1c≥7% than in the T2DM patients with HbA1c<7%, but not statistically significant (0.44±0.30 
vs 0.32±0.22; p= 0.183). The total atrial conduction time was longer in the T2DM patients with 
HbA1c≥7% than in T2DM patients with HbA1c<7%, but not statistically significant (100.29±28.53 
vs 94.88±16.50; p= 0.449). Multiple regression analysis showed that hsCRP levels and glycemic 
control had significant positive correlation with total interatrial conduction time in T2DM patients 
(r= 0.51; p= 0.004). 
Conclusion: The hsCRP levels and glycemic control were significant positively correlated with 
total interatrium conduction time in patients with type 2 diabetes. 
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BACKGROUND 
 
Diabetes mellitus (DM) and cardiovascular 
disease often appear as two sides of a coin. 
DM is considered equivalent to coronary 
heart disease (Maqri and Fava, 2012). As a 
consequence, the mortality and incidence of 
all forms of cardiovascular disease in 
people with higher DM two to eight times 
higher than in people without diabetes are 
risk factors for arrhythmia. The risk factors 
which act as arrhythmogenic substrate in 
patients with diabetes involves the auto-
nomic nervous system disorders, ischemia, 
conduction time interatrium elongation, 
heterogeneous repolarization in the atria 
and ventricles, myocardial damage and scar 
formation (Nakou et al., 2012). 
Based on a meta-analysis study, the 
current risk of atrial fibrillation increased 
significantly in diabetic patients (Zhang et 
al., 2014). DM is a risk factor independent 
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of atrial fibrillation (Watanabe et al., 2012). 
Study Framingham Heart Study states that 
diabetes is proven as a cause of new-onset 
atrial fibrillation in a cohort study of men 
and women who were followed for 38 years 
(OR 1.4 for men and 1.6 for women) (Nakou 
et al., 2012). Study recent meta-analysis 
indicate that individuals with diabetes have 
a risk of> 40% to occur atrial fibrillation 
than individuals without diabetes (Liu et 
al., 2012). This risk will increase the longer 
duration of diabetes and the poor glycemic 
control (Dublin et al., 2010). Atrial fibrillat-
ion is a marker of poor prognosis in pa-
tients with DM (Lin et al., 2013). Atrial 
fibrillation risk> 60% of all causes of mor-
tality and have a higher risk to cardio-
vascular death, stroke, and heart failure. 
However, the contribution of diabetes on 
the prevalence and incidence of atrial 
fibrillation still requires a variety of ad-
vanced study (Goudis et al., 2015). 
The atrial fibrillation pathophysiology 
in patients with diabetic is not known yet 
(Liu et al., 2012; Yazici et al., 2007). The 
presence of arrhythmogenic atrial remodel-
ing is expected to have an important role in 
the pathophysiology of atrial fibrillation in 
patients with diabetes. Arrhythmogenic atri-
al remodeling is defined as the change in 
the structure and function of the atria that 
can trigger atrial arrhythmias such as atrial 
fibrillation (Nattel and Harada, 2014). Pa-
thophysiology of atrial fibrillation in dia-
betes include: remodeling autonomous sys-
tems, electrical, electromechanical, and 
anatomy due to oxidative stress, remodel-
ing up my, and fluctuations in blood sugar 
(Goudis et al., 2015). Remodeling anatomy 
can be a major substrate of atrial fibril-
lation occurrence in diabetes (Liu et al, 
2014). The substrate of atrial fibrillation is 
the electrical function abnormalities in 
atrial tissue itself (Quintana et al., 2012). 
Study Kato et al (2008) reported a inter-
atrium conduction disturbances due to 
atrial interstitial fibrosis which can be a key 
substrate initiation of atrial fibrillation. 
Hyperglycemia cause atrial dilatation and 
interstitial fibrosis, as well as electrical 
remodeling re-sulting in a prolongation of 
the conduction time interatrium and in-
creased susceptibility to atrial fibrillation 
(Liu et al, 2014). 
Changes in the form of electrical sys-
tems in the form of shortening atrial re-
fractory period of the atrium and sinus im-
pulse propagation is not homogeneous the 
electrophysiological characteristics that tend 
to cause atrial fibrillation (Bakirci et al., 
2015). Shortening of the atrial refractory 
period and propagation of sinus impulses 
are not homogeneous cause prolongation of 
the conduction time interatrium. As a result 
there is a delay between electrical activation 
of the mechanical contraction that atrial 
electromechanical function impaired (Gou-
dis et al., 2015). Interatrial conduction time 
total reflects atrial electromechanical func-
tion and can be used as a marker of atrial 
remodeling remodeling both electric and 
anatomy (Uijl et al., 2011; Deniz et al., 
2012). Elongation interatrium conduction 
time is closely related to the mechanisms 
underlying abnormalities in the atrium 
directly or indirectly, and one of the con-
ditions for the initiation and development 
of atrial fibrillation (Weijs et al., 2011). 
Elongation interatrium total conduction 
time has been proven to increase the risk of 
atrial fibrillation in many studies (Antoni et 
al., 2010). Various different methods can be 
used to evaluate the total interatrium 
conduction time. Although electrocardio-
graphy and echo cardiography examination 
is used to measure the conduction time 
interatrium, cardiac electrophysiology exa-
mination is still the gold standard examina-
tion (Merckx et al., 2005). Currently, echo-
cardiography with dopler networks are often 
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used to measure the conduction time inter-
atrium in various studies. Although it is not 
the gold standard examination, this exami-
nation is preferred to measure conduction 
time interatrium because it is non-invasive 
and the results are believed to correspond 
to the examination of cardiac electro-
physiology (Fatma et al., 2015). Previous 
study indicates total elongation conduction 
time interatrium a strong predictor of the 
incidence of atrial fibrillation (Weijs et al., 
2011). 
Various data also showed that the 
longer the duration of diabetes or for worse 
glycemic control, also increase the risk of 
atrial fibrillation (Dublin et al., 2010). 
Study Dublin et al., (2010) reported that 
there is a significant correlation between 
HbA1C levels with risk of atrial fibrillation. 
The study showed that each increase by 1% 
in HbA1c levels associated with an increas-
ed relative risk of atrial fibrillation 1:14 
(95% CI= 0.96 to 1:35). Therefore, there is 
a free relationship between DM and poor 
HbA1c levels with an increased risk of atrial 
fibrillation. However, the contribution of 
diabetes on the prevalence and incidence of 
atrial fibrillation is based on glycemic 
control still needs further studies (Zhang et 
al., 2014). 
DM has been associated with the 
production of excessive reactive oxygen 
species and decreased antioxidant capacity, 
resulting in tissue damage (Stadler, 2012). 
Various studies have also reported that 
inflammation and oxidativestress play a 
role in atrial electrical remodeling anatomy 
and thus plays an important role in the 
formation and development of atrial fibril-
lation (Ozaydin 2010; Korantzopoulos et 
al., 2007; Rudolph et al., 2010). Inflam-
mation and oxidative stress is thought to be 
one cause of atrial interstitial fibrosis and 
atrial electromechanical function disorders, 
thereby facilitating the occurrence and de-
velopment of atrial fibrillation (Fu et al., 
2013; Liu and Li, 2008). Systemic inflam-
mation in diabetes increases levels of C-
reactive protein (CRP) that predispose 
occur atrial fibrillation. Local activation of 
the complement system mediated by 
binding of CRP with phospholipid compo-
nents of damaged cells (Antonio, 2006). 
Examination of high-sensitivity C-reactive 
protein (hsCRP) is a marker of systemic 
inflammation and tissue damage that can 
predict the risk of cardiovascular disease 
(Antonio, 2006). Various studies also 
showed elevated levels of hsCRP be a strong 
predictor of atrial fibrillation (Galea et al., 
2014). However, there has been no consi-
derable literature on the relationship of 
atrial fibrillation with inflammation in 
diabetic patients (Bakirci et al., 2015). 
Currently, there are no studies on the 
effect of inflammation on interatrial con-
duction time total which is a predictor of 
early development of atrial fibrillation in 
patients with type 2 diabetes based on gly-
cemic control. Therefore, the authors want-
ed to examine a possible relationship bet-
ween hsCRP levels and glycemic control 
with total interatrium conduction time in 
patients with type 2 diabetes. 
 
SUBJECTS AND METHOD 
 
This was an analytic-observational study 
with cross sectional design. It was conduc-
ted on April 2016 in the installation of the 
Outpatients Clinic of Internal Medicine at 
Dr. Moewardi Hospital, Surakarta. There 
were forty one patients with type 2 diabetes 
mellitus selected for this study. The 
inclusion criteria were patients aged >18 
years with sinus rhythm based on the 
examination of electrocardiography (ECG). 
The exclusion criteria in this study were 
malignancy, liver cirrhosis, immunological 
disease (both immunodeficiency diseases 
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and auto-immune), systemic infection (by 
clinical examination, white blood cell 
count> 12 x 109/ mL, or a temperature >37. 
50C), and the use of drugs and non-steroid-
al anti-inflammatory steroid 1 last month. 
Echocardiography performed using 
GE Vivid S6. During echocardiography, 
patients underwent ECG recording. Dop-
pler Tissue Imaging (TDI) examination 
measured the total interatrial conduction 
time (Interval PA-TDI). PA-TDI interval 
defined as the time interval from the initia-
tion of the P wave in electrocardiography 
recorded on echocardiographic tool (lead 
II) until the crest of the wave A in the 
picture Doppler atrial tissue which mea-
sured three times of cardiac cycle and 
averaged. Abnormality measurements per-
formed such as stenosis or regurgitation of 
heart valves, segmental analysis, the exis-
tence of anatomical abnormalities, the di-
mensions of heart chambers, left ventri-
cular function. 
HsCRP examination performed before 
or after the echocardiographic data retriev-
al. HsCRP blood samples were taken from 
the antecubital vein processing. It conduct-
ed at the Laboratory of Clinical Pathology, 
Dr. Moewardi Hospital. HsCRP examinat-
ion was using Latex immunoturbidimetry 
on ADVIA 1800 Chemistry Suste (Siemens 
Healthcare Diagnostic, Deerfield, IL). 
Multiple linier regression analysis was 
used to analyze the relationship between 
hsCRP and glycemic control (HbA1c levels) 
with a total interatrial conduction time with 
the following formula:   
Y = interatrium total conduction time 
(continuous data) 
X1 =  hsCRP (continuous data) 
X2 = glycemic control based on HbA1c 
(categorical data) 
β0, β1, β2 = coefficient regression 
The correlation coefficient (r) indi-
cates how the relationship between hsCRP 
levels and glycemic control simultaneously 
the conduction time interatrial total. R ra-
nges from 0 to 1 means that the relation-
ship is getting stronger. Guidelines to pro-
vide interpretation of correlation coefficient 
as follows: 
to 0.199 = very low 
0.20 to 0.399 = low 
0.40 to 0.599 = moderate 
0.60 to 7.99 = strong 
0.80 to 1.000 = very strong 
The coefficient of determination (R2) is the 
coefficient used to determine how much 
hsCRP and glycemic control affects the 
conduction time interatrial total. This coef-
ficient shows how much percentage of va-
riation of hsCRP and glycemic control was  
able to explain the variation in total inter-
atrial conduction time. The p-value <0.05o 
states the difference statistically significant. 
Data analysis measured using SPSS (versi-
on 22.0;SPSS Inc., chicago, IL, USA). 
 
RESULTS 
 
Subject of the study consisted of 17 patients 
with type 2 diabetes with HbA1c <7% 
(mean age 63.12 ± 9.38 years; 22.7% men) 
and 24 patients with type 2 diabetes with 
HbA1c ≥ 7% (mean age 58, 33 ± 9.41 years; 
11.4% men). From Table 1 the characteris-
tics of the subjects with well-controlled 
blood sugar (HbA1c <7%) and poorly con-
trolled blood sugar (HbA1c ≥7%) did not 
differ significantly (p> 0.050). Type 2 
diabetes patients with HbA1c ≥ 7% had 
higher hsCRP levels compared to patients 
with type 2 diabetes with HbA1c <7%, but 
not statistically significant (0.44 ± 0.30 
versus 0.32 ± 0.22; p = 0.183). 
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Tabel 1. Characteristic of clinic and laboratory data in DM type 2 
 HbA1c <7% (n = 17) HbA1c ≥7% (n = 24) p 
Age, Year 
Gender, male (%) 
BMI (kg/m2) 
Smoking (%) 
Blood pressure (mmHg) 
     <140/90 
     ≥140/90 
Pulse rate (Pulse/minute) 
Illness duration (%) 
     < 5 years 
     5-10 years 
     ≥ 10 years 
Coronary heart disease (%) 
Valvular heart disease (%) 
hsCRP (mg/L) 
63.12 ± 9.38 
22.7 
24.56 ± 4.30 
6.8 
 
18.2 
20.5 
82.00 ± 8.00 
 
18.2 
15.9 
4.5 
4.5 
9.1 
0.32 ± 0.22 
58.33 ± 9.41 
11.4 
25.73 ± 3.91 
18.2 
 
15.9 
38.6 
79.29 ± 11.83 
 
11.4 
27.3 
15.9 
11.4 
6.8 
0.44 ± 0.30   
0.117 
0.200 
0.378 
0.157 
0.059 
 
 
0.387 
0.317 
 
 
 
0.414 
0.655 
0.183 
Glycated Haemoglobin (HbA1c); Body Mass Index (BMI); Systolic Blood Pressure(SBP); Diastolic Blood 
Pressure (DBP); high sensitivity C-reactive protein (hsCRP). 
 
Table 2. Characteristics of echocardiography in subjects with type 2 Diabetes 
 Hba1c <7% (N = 17) Hba1c ≥7% (N = 24) p 
Left Ventricular Ejection Fraction (%) 
Left Atrial Diameter (Mm) 
Ratio E/A 
Ratio Em/Am 
Ratio E/Em 
Total of interatrial conduction time (Ms) 
65.71 ± 10.13 
31.65 ± 5.88 
0.78 ± 0.21 
0.85 ± 0,31 
7.08 ± 2.97 
94.88 ± 16.50 
59.33 ± 15.87 
31.29 ± 5.66 
0.92 ± 0.49 
0.83 ± 0.32 
8.46 ± 3.96 
100.29 ± 28.53 
0.125 
0.848 
0.272 
0.827 
0.210 
0.449 
E, Mitral Annular Early Diastolic Velocity; A, Mitral Annular Late Diastolic Velocity; Em, Tissue 
Doppler Mitral Annular Early Diastolic Velocity; Am, Tissue Doppler Mitral Annular Late Diastolic 
Velocity; Mm, Millimeter; Ms, Miliseconds. 
 
Table 3. The results of multiple linear regression analysis of the association between hsCRP 
levels and glycemic control (HbA1c) with a total interatrial conduction time in patients with 
type 2 Diabetes Mellitus. 
Variables β 
95% CI 
p 
Lower Upper 
Contants  
hsCRP (mg/dL) 
HbA1c ≥7%  
77.54 
38.78 
14.04 
64.19 
14.01 
0.09 
90.89 
63.54 
27.98 
<0.001 
0.003 
0.048 
N observation= 41 subjects 
Correlation Coefficient (R)= 051 
Determination Coefficient (R2)= 21.6% 
p = 0.004 
 
In Table 2 echocardiographic charac-
teristics of subjects with well-controlled 
blood glucose (HbA1c<7%) and poorly con-
trolled blood sugar (HbA1c≥7%) did not 
differ significantly (p>0.050). Total atrial 
conduction time in patients with type 2 
diabetes with HbA1c ≥ 7% longer compared 
with patients with type 2. 
Diabetes with HbA1c <7%, but not 
statistically significant (100.29 ± 28.53 
versus 94.88 ± 16.50; p= 0.449). Multiple 
regression analysis was conducted to deter-
mine whether there is a relationship bet-
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ween hsCRP levels and glycemic control 
with total interatrial conduction time in 
patients in this study. 
Based on the results, it appears that 
there is a moderate correlation between 
hsCRP levels and glycemic control with a 
total interatrial conduction time. The coeff-
icient of determination shows that percent-
age contribution and influence of glycemic 
control hsCRP the conduction time inter-
atrial 21.6%. Seventy eight percent in-
fluenced other variables not included in 
this study.The equation was found that 
each increase of hsCRP then interatrial 
total conduction time of 38.78 milliseconds. 
In HbA1c ≥7% the total interatrial con-
duction time would be increase of 14.04 
milliseconds (p=0.004). It shows that the 
obtained results were statistically signifi-
cant.  
 
DISCUSSION 
 
This study showed that hsCRP levels and 
glycemic control (HbA1c) correlated posi-
tive with the total interatrial conduction 
time in patients with type 2 diabetes. 
Epidemiological studies have shown that 
the incidence of atrial fibrillation was 
higher in patients with type 2 diabetes 
compared with normal subjects (Johansen 
et al., 2008). Atrial fibrillation is the most 
common cardiac arrhythmia that increased 
morbidity and mortality, including stroke, 
heart failure, and decreased quality of life 
(Voigt and Dobrev, 2012; Yuniadi et al., 
2014). Patients with atrial fibrillation at 
risk of stroke five times and heart failure 
three times higher than the patients 
without atrial fibrillation (Yuniadi et al., 
2014).  
Currently, the number of patients 
with atrial fibrillation increase, so the 
primary prevention of the new onset atrial 
fibrillation important to do. Primary pre-
vention strategies can be done if the 
clinician is able to identify patients at high 
risk for the occurrence of atrial fibrillation 
(Vos et al, 2009). Pathophysiology that 
cause diabetes predispose to atrial fibrill-
ation include ventricular hypertrophy, is-
chemia/ fibrosis of the myocardium, re-
modeling of the left atrium, impaired auto-
nomic tone and inflammation (Liu et al, 
2009). Hayden et al., (2006) showed that 
high blood glucose levels can induce myo-
cardial fibrosis in rats.  In addition, patients 
with diabetes higher levels of C-reacsive 
higher protein, a markeer systemic in-
flammation, which lead to myocardial 
fibrosis and diastolic dysfunction (Yuan et 
al, 2006). The risk coronary heart disease 
and heart failure was higher in patients 
with diabetes increased the incidence of 
atrial fibrillation (Dublin et al, 2010). 
 This study demonstrated a positive 
linear relationship between HbA1c levels 
with a total of interatial conduction time, 
where HbA1c ≥7% the total of interatrial 
conduction time would increase of 14.04 
milliseconds. Risk of atrial fibrillation in 
patients with diabetes is associated with 
glycemic control (Fatemi et al., 2014). 
Huxley et al., (2012) showed a posi-
tive linear relationship between HbA1c with 
risk of atrial fibrillation in diabetic patients 
with an odds ratio of 1.13 per 1% increase in 
HbA1c levels. Therefore, diabetes and poor 
glycemic control, as measured by A1C, 
associated with an increased risk of atrial 
fibrillation. Interatrial total conduction 
time measured by echocardiography dopp-
ler network (PA-TDI).  It reflects atrial acti-
vation that used to detect atrial electro-
mechanical interference (Hata et al, 2014). 
Remodeling atrium can be detected from 
presence of atrial conduction disturbance 
and dispersion of atrial refractory period, 
which trigger reentry process and the onset 
of atrial fibrillation (Bakirci et al., 2015). 
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Interatrial total conduction time is the 
time from initiation to the end of the atrial 
depolarization activation of the same place. 
Elongation conduction time interatrium 
total reflecting decreased conduction velo-
city and atrial dilatation can be a substrate 
for the occurrence of atrial fibrillation 
(Heijman et al., 2014). Decrease in conduc-
tion velocity cause shortening circuit or 
path of action potential depolarization and 
occur repeatedly, causing micro reentry 
(multiple wavelet reentry). Reentry mecha-
nism is one of the occurrence of atrial 
fibrillation (Represents et al., 2011). So, the 
measurement of total interatrial conduction 
time can be used as predictor of incident 
atrial fibrillation (Ozlu et al., 2013; Vos et 
al., 2009). 
Vos et al., (2009) showed that the total 
interatrial conduction time is short (<130 
milliseconds) can prevent patients from 
atrial fibrillation events. So clinicians can 
consider this patient is not a candidate to 
do primary prevention of the occurrence of 
atrial fibrillation. Patients with conduction 
time interatrial total >165 milliseconds at 
risk for atrial fibrillation occurs and may be 
a candidate for the primary prevention of 
the occurrence of atrial fibrillation using 
cardiovascular drugs. Patients with co-
nduction time interatrial total >190 milli-
seconds very risky to occur atrial fibril-
lation. These patients can be treated with 
anticoagulants prophylactically, especially 
if the patient has a score CHADS2 (conges-
tive heart failure, hypertension, age = 75 
years, diabetes mellitus, stroke) is high 
(Vos et al., 2009). CHADS2 score is used to 
predict the risk of stroke in patients with 
atrial fibrillation non valves (Lane and Lip, 
2012). 
Liu et al (2012) showed that atrial elec-
tromechanical function disorders associat-
ed with increased total interatrium con-
duction time. Kato et al., (2006) showed 
interatrial conduction time delays and in-
creased deposition of fibrotic atrium plays 
an important role in the incidence of atrial 
arrhythmogenic. This indicates that the 
structure of atrial remodeling characterized 
by interstitial fibrosis may be one of the 
main mechanisms of the occurrence of 
atrial fibrillation in DM (Kato et al., 2006). 
Fu et al., (2013) detected conduction time 
interatrial total lengthwise on rabbit 
diabetes than the control group. But 
certainly elongation pathophysiology inter-
atrial conduction time in patients with 
diabetes is still unknown. This study shows 
that there is a positive correlation between 
the hsCRP with intreatrial conduction time. 
Interatrial conduction time would be in-
creased of 38.78 milliseconds in every unit 
of hsCRP unit increased. Histological 
examination showed infiltrates of inflam-
matory and oxidative damage to the atrial 
tissue in patients with atrial fibrillation 
(Boss et al., 2006). Liu et al, 2008) showed 
that inflammation is one of the mecha-
nisms of atrial fibrillation in patients with 
diabetes. Inflammatory stimulus triggering 
fibroblast proliferation, migration, and 
transformation also miofibroblas causes 
atrial remodeling characterized by shorten-
ing of atrial refractory period (Friederichs 
et al., 2011). Various studies have observed 
the relationship of inflammation in atrial 
fibrillation with inflammatory markers 
such as CRP, hsCRP, and interleukin (IL) -6 
(Boos et al., 2006). Bakirci et al (2015) 
demonstrated total conduction time inter-
atrium positively correlated with CRP levels 
in patients with type 2 diabetes mellitus. 
Oxidative stress and inflammation are also 
a key component and is associated with 
poor glycemic control, the pathogenesis of 
diabetes and its complications (Gohel and 
Chacko, 2013). Sarinnapakorn et al., (2013) 
showed levels of hsCRP were positively 
correlated with HbA1c levels where the 
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mean HbA1c levels were significantly high-
er in patients with hsCRP levels ≥ 1 mg / L. 
Other factors such as age, blood pressure, 
body mass index, LDL cholesterol, serum 
creatinine did not correlate with levels of 
hsCRP (Sarinnapakorn et al., 2013). Bah-
ceci et al (2005) showed no significant 
difference in hsCRP levels in patients with 
type 2 diabetes without coronary heart 
disease in patients with non-type 2 diabetes 
have coronary heart disease. But type 2 
diabetes patients who had coronary artery 
disease have higher levels of hsCRP than 
patients with non-type 2 diabetes and coro-
nary heart disease (Bahceci et al., 2006). 
Therefore, oxidative stress and inflam-
matory markers can be used as an addition-
al examination in addition to HbA1c to 
assess cardiovascular risk in diabetic pa-
tients with poor glycemic control (Dilshad 
and Shazia, 2009). 
In addition to glycemic control, car-
diovascular risk factors such as dyslipide-
mia, hypertension, smoking, and obesity 
may influence the inflammatory status of 
individuals (Montori, 2008). HsCRP levels 
in this study had a fairly large standard 
deviation in both subjects with well-con-
trolled blood glucose and poorly controlled 
(0.32±0.22 versus 0.44±0.30). This indi-
cates blood glucose control alone cannot be 
used to determine the status of inflam-
mation. 
Based on multivariate analysis, hs-
CRP levels and glycemic control correlated 
(positively) moderate (OR=0.51; p=0.004) 
with total interatrial conduction time. 
Studyers simply observe the relationship of 
inflammation and glycemic control with 
total interatrial conduction time. However, 
a variety of other causes, such as cardiac 
remodeling autonomous system, activation 
of the renin angiotensin aldosterone 
system, sympathetic over activity, changes 
in fibrosis due to hyperglycemia, all of 
which may lead to an increase in the 
frequency of atrial fibrillation and the 
deterioration of the function of the left 
atrium, can cause prolongation of the cond-
uction time interatrium total. Hypertens-
ion, a history of paroxysmal atrial fibril-
lation, heart valve abnormalities, increas-
ingly older age and body mass index were 
higher also can prolong the conduction 
time interatrial total (Weijs et al., 2011). 
Characteristics of the subjects with 
poorly controlled blood glucose have a body 
mass index higher, more hypertension, and 
diabetes duration longer than subjects with 
well-controlled blood sugar. This study 
shows the percentage contribution of the 
influence of hsCRP and glycemic control of 
the conduction time interatrial 21.6%. 
While the rest of 78.4% may be affected by 
other variables such as body mass index, 
hypertension, duration of diabetes, and a 
history of paroxysmal atrial fibrillation. 
Various echocardiographic parame-
ters can be correlated with total interatrial 
conduction time. The increase in left atrial 
dimension, increasing the diameter of the 
aortic, mitral and aortic regurgitation and 
diastolic dysfunction associated with pro-
longation of the conduction time interatrial 
total. Mild diastolic dysfunction may be a 
sign of ventricular relaxation disorders. The 
increase in left atrial dimension may reflect 
an increase in left atrial pressure that can 
occur in left ventricular diastolic dys-
function (Weijs et al., 2011). 
However, the validation study demon-
strated an electromechanical process is 
constant. In addition, the slightest delay 
time when the ECG processing occurs on all 
machines echocardiography. However, this 
delay is consistent so it should not interfere 
with the results of this study. Other research-
er also cannot detect paroxysmal atrial fi-
brillation episodes that may have occurred 
on the subject of study, because they do an 
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EKG only one time of the study. Further-
more, diabetic neuropathy which is not 
visible can mask the symptoms of atrial 
fibrillation-related heart. 
Echocardiography measurement con-
venient form of measurement conduction 
time interatrial total help identify patients 
with type 2 diabetes (especially those that 
have the status of glycemic control was bad 
and elevated levels of hsCRP). A risk of 
atrial fibrillation, so primary prevention 
can be done more effectively by reducing 
the number of patients treated (number 
needed to treat). However, these results 
need to be validated with a cohort study to 
strengthen the scientific evidence.  
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